Home  /  Resource Library  /  Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)

Can nivolumab alone cure patients with relapse or refractory Hodgkin lymphoma? A 5-year analysis of the French early access program (EPA)

Analysis examined Nivolumab for treatment of relapsed Hodgkin lymphoma.